Biotechnology is one of the most progressive and beneficial scientific advances of the last quarter century. An interdisciplinary field that includes mathematics, physics, chemistry, engineering and others, it combines various- technologies to either create a new product or modify an existing one to suit our needs.

Its widespread application across multiple industries like food, pharmaceutical, chemical, bio-products, textiles, medicine, nutrition, environmental conservation and animal sciences makes a career in biotechnology one of the fastest growing fields with ample opportunities for qualified professionals.

Biotechnology combines the theoretical (genetics, molecular biology, biochemistry, embryology and cell biology), and the practical (chemical engineering, information technology and robotics)scientific aptitude, a keen interest in the biological sciences, problem solving skills. An analytical mind is essential for successful career in biotechnology.

The candidate should be methodical and patient by nature, able to work neatly and accurately and have a flair for laboratory work. The ability to work independently is another important aspect. The knowledge of computers is a must.

10 + 2 science stream graduates can opt for a B.Tech (Biotechnology) or an integrated M. Tech (Biotechnology); science stream graduates from any field (engineering, medicine etc.) can opt for a M. Tech (Biotechnology).

IIT Delhi and Kharagpur offer admission into a five year integrated M.Tech through a Joint Entrance Examination.

The Jawaharlal Nehru University, New Delhi conducts an all-India entrance examination for their Msc Biotechnology program.

Any candidate with an undergraduate degree from a 10+2+3 system with at least 55% marks in:

Is eligible to apply for the JNU Msc(Biotechnology) as well as others.

The Department of Biotechnology (DBT) also offers postgraduate courses in selected institutions, and through four prominent research institutes, further provides a two-year support for post doctoral programs; the objective is to prepare long term biotech professionals and scientists for frontier research and advance research methodologies.

Two other institutes, backed by the DBT, provide a one-year MD/MS training in medical biotech. The cover fields such as:

SRM University offers B.Tech in Biotechnology, Genetic Engineering, and Bioinformatics. They also offer an M.Tech in Biotechnology and Biomedical Engineering.

Applications Forms Now Available

Affordable and intelligent R&D partnering with Chinese and American corporate bodies has great scope in mining Indias biotech potential and co-developing tech; India has a global market worth a $91 billion. Thats why so many global pharma companies are flocking to India for their own R&D initiatives.

A bio-technologist may find jobs in various quarters. Biotechnology jobs in India can be found in the following fields:

While government institutes and organizations, such as Department of Biotechnology (DBT), several agriculture, dairy and horticulture institutes may offer job opportunities to Biotechnology professionals, one can expect the best salary in private sector.

Drug companies in biotechnology like Dabur, Ranbaxy, Hindustan Lever and Dr Reddy's Labs that have their R & D units offer Biotechnology professionals with handsome pay-packages. There are also ample opportunities available to bio-technologists in the food processing industry, chemical industry and the textile industry.

Some industries employ bio-technologists in their marketing divisions to develop business in sectors where their products would be required.

The major companies, hiring bio-technologists, include Hindustan Lever, Thapar Group, Indo American Hybrid Seeds, Bincon India Ltd., IDPL and Hindustan Antibiotics.

The Government of India provides large-scale employment to most bio-technologists in its research laboratories. Those employed as researchers in government sector can have a starting salary of Rs. 9000 per month along with government perks/allowances.

Private sector pharmaceutical companies generally offer salary between Rs. 12,000- Rs. 20,000 per month to an entry-level postgraduate. A skilled and experienced bio-technologist can get salaries far beyond his expectations.

Indian Institute Of Technology

Indian Institute Of Technology

Vellore Institute Of Technology

Indian Institute Of Technology, Guwahati

National Institute Of Technology, Warangal

PSG College Of Technology

National Institute Of Technology, Durgapur

Manipal Institute Of Technology

BMS College of Engineering

Chaitanya Bharathi Institute of Technology

PES Institute of Technology

SASTRA University

National Institute of Technology, Raipur

GITAM University

Karunya University

Note: Selection through All India Combined Entrance Test

Courses Offered : B.Tech in Biotechnology, Genetic Engineering, and Bioinformatics. M.Tech in Biotechnology and Biomedical Engineering

See the original post:
Biotechnology Career | Jobs, Salary, Courses & Colleges in ...

UK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc's share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.

Oxford Immunotec said it will use the proceeds from the offering for working capital and general corporate purposes. The companys immunodiagnostic T-SPOT platform is measures immune cell responses at a single cell level and thus detects immune responses of T cells and cells of the innate immune system more sensitive than ELISA assays. According to the British company, its assays can detect an individual reacting cell in a population of 250,000 white blood cells.

Oxford Immunotecs first product, the T-SPOT.TB test, has been approved for sale in over 50 countries, including the US, the EU, Japan and China. The companys second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The company currently is seeking FDA approval for its third product line, a screening test for Babesia in donated blood. Additionally Oxford Immunotec has several assays, such T-SPOT.CMV test and the T-SPOT.PRT under development.

Excerpt from:
Oxford Immunotec value drops after public offering - European Biotechnology

Science has multiple wings and streams and studying one of them and specializing in it can open up various career prospects for the candidates. A couple of such streams that are gaining importance and popularity are biotechnology and microbiology. Both are integral parts of biological science and both have their respective uses. Pursuing a graduation or masters degree in the field may prove extremely rewarding for the users. Many students these days are pursuing the BSc Biotechnology and higher degrees in search of building up their career graph.

Understanding Biotechnology

Biotechnology involves the use of genetic as well as biochemical processes related to the living organisms for using them for humans. There are numerous genetically modified crops in the field of agriculture and there are also multiple genetically modified vaccines in the field of healthcare and medications. In some of the leading science colleges in Dehradun particular emphasis is given to the application of the principles of biotechnology in DNA applications and cell regulation in human anatomy. While the BSc degrees offered by these colleges include basic applications in the field the MSc Biotechnology degree offers higher levels of use of the biochemical processes and their impact studies.

Work Placement and Laboratory Works

Students seeking to obtain the MSc Biotechnology degree may not find the task easy enough. There are very strong optional work placements involved and the course also includes high degrees of laboratory works. This ensures practical experience induction in the student preparing him or her to be strong enough to face all the challenges that come their way. Thus the courses are intelligent combination of theories and practices.

Biotechnology Course Components

Course components for the students studying for obtaining graduation or masters degree in biotechnology include biology, chemistry, and mathematics. Physics is not normally included but students can separately study physics and even go up to the level of passing MSc Physics. In degree courses there are no majors. Students may however opt to specialize in a subject and choose the honors course in it. Taking honors has two benefits. First it can enhance job prospects and second it would make entry into the MSc course easier.

Job Prospects in the Field

People with graduate or masters degree in biotechnology get job opportunities in a host of industries. These are pharmaceuticals, environment, agriculture, horticulture, research, and forensic science among others. Job opportunities are available in both public as well as private sectors. Consulting services, academes, research organizations and NGOs are other major job sources.

Study of Microbiology

An important wing of biotechnology is microbiology that deals with organisms in microscopic sizes. They include bacteria, viruses, protozoa and algae as well as fungi affecting the life of human beings. Studying their characteristics, impact on human anatomy and remedial solutions constitute the basic features of the MSc Microbiology.

Biotechnology is not a new invention and has been in use for over six thousand years. The technology has been used to prepare foodstuff like bread and cheese, for preservation of dairy products and also for fermenting beer. Candidates need a good college to pursue their course of BSC or MSc Microbiology or any other wing of the biotechnology. To choose the right academy the need information and a qualitative site can provide the required information for them.

Know more visit http://bfitdoon.com/

Photo By PublicDomainPictures from Pixabay

Continue reading here:
Studying Biotechnology And Microbiology For Career Building ... - Good Herald

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Academic" conference to their offering.

The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference.

This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference.

The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international academic and corporate biotechnology communities.

Benefits of Attending

- Exchange ideas and network with leading biotechnologists and decision makers.

- Bring together top international biotechnology professionals presenting cutting-edge discoveries, research and opportunities for new biotech business practices and partnerships.

- Participants can gain direct access to a core audience of biotechnology professionals and decision makers, and have increased visibility through branding and networking at the conference.

- Obtain a global roundup of Pharmaceutical research capabilities and opportunities.

- The conference will feature a commercial exhibition and poster sessions.

For more information about this conference visit http://www.researchandmarkets.com/research/tw4sc3/global

See original here:
Global Biotechnology Congress 2017: Academic Registration ... - Business Wire (press release)

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Puma did not anticipate that the U.S. Food and Drug Administration ("FDA") would ultimately approve PB272 ("neratinib") for the treatment of breast cancer; (2) consequently, Puma Biotechnology had overstated the drug's approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology's public statements were materially false and misleading at all relevant times.

On May 4, 2017, post-market, Puma revealed that Dr. Robert Charnas, the Company's Senior Vice President, Regulatory Affairs, would be stepping down for "health reasons." Dr. Charnas's resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration's scheduled review of Puma's breast cancer drug neratinib on May 24. Following this news, Puma stock dropped.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: http://www.bgandg.com/pbyi or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Puma you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-puma-biotechnology-inc-pbyi-and-lead-plaintiff-deadline-july-7-2017-300456300.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Homepage

Read the original:
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma ... - PR Newswire (press release)

The Cerbat Gem

JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) The Cerbat Gem iShares NASDAQ Biotechnology Index logo JPMorgan Chase & Co. raised its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 45.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional ... iShares NASDAQ Biotechnology Index (IBB) Receiving Somewhat Favorable Media Coverage, Analysis ShowsSports Perspectives iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Folger Nolan Fleming Douglas Capital Management Inc.Chaffey Breeze The Ameriprise Financial Inc. Increases Stake in iShares NASDAQ Biotechnology Index (IBB)BangaloreWeekly all 10 news articles »

Read more from the original source:
JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Advances in science, many of them from scientists at USDA or through research funded by USDA, have opened up new options for farmers responding to market needs and environmental challenges. Many new plant varieties being developed or grown by farmers have been produced using genetic engineering, which involves manipulating the plant's genes through techniques of modern molecular biology often referred to as recombinant DNA technology. These techniques are included in what is often referred to as "biotechnology" or "modern biotechnology."

USDA supports the safe and appropriate use of science and technology, including biotechnology, to help meet agricultural challenges and consumer needs of the 21st century. USDA plays a key role in assuring that biotechnology plants and products derived from these plants are safe to be grown and used in the United States. Once these plants and products enter commerce, USDA supports bringing these and other products to the worldwide marketplace.

Three federal agencies are involved in ensuring that plants produced using biotechnology and the many products derived from them are safe for farmers to use, safe to consume as food or feed, and safe for the environment. These are USDA's Animal and Plant Health Inspection Service, the Department of Health and Human Services' Food and Drug Administration, and the United States Environmental Protection Agency. The three agencies regulate these products based on the characteristics of the actual products and their intended uses, and they operate under the existing laws passed by Congress to ensure the safety of plants used in agriculture, the safety of pesticides used in agriculture, and the safety of foods we eat and feeds given to animals. Many other USDA agencies have roles in the development, use, and marketing of these products as well.

Learn more about How the U.S. Government Regulates Biotech Plants.

Since the first successful commercialization of a biotechnology-derived crop in the 1990s, many new crop varieties have been developed and made available to U.S. farmers and farmers worldwide. U.S. farmers have rapidly adopted many of these new GE varieties, so that in 2012, 88 percent of the corn, 94 percent of the cotton, and 93 percent of the soybeans planted in the U.S. were varieties produced through genetic engineering. A large proportion of the production of other crops, such as alfalfa, and papaya, and sugar beet, is also biotech-derived.

Read more about the reasons behind this trend and about how farming practices and the marketplace have changed on USDA's Economic Research Service Biotechnology page.

The United States is the largest exporter of agricultural products, which helps feed the world's population, and our export markets are critical to the health of U.S. farm communities around the country. Most of the corn and soybeans we export are biotechnology-derived, and this means that working with our trading partners is critical to help them understand the technical aspects of new products and how we have determined that they meet our high safety standards, to open up new markets, and to ensure that our products are treated fairly in the global marketplace.

The increasing use of biotechnology in agriculture has changed, and will continue to change, farming and the work of USDA in the long-term. To help understand and address these changes, USDA established the Advisory Committee on Biotechnology and 21st Century Agriculture (AC21). One critical area where the committee has focused its attention is how farmers who produce different crops intended for different customers-biotechnology-derived, conventional, or organic-can best co-exist and produce the crops that meet their customers' needs. The AC21 has provided a report to USDA, with recommendations, on this subject.

Visit the AC21 page to learn more.

Continue reading here:
Biotechnology | USDA

SAN FRANCISCO--(BUSINESS WIRE)--

DevonWay, Silicon Valleys leading provider of continuous improvement software to large enterprises, announced today its expansion into a new industry with the adoption of a global, Fortune 500 biotechnology client.

Biotechs emphasis on safety, quality, reliability, and innovation make it a natural fit for DevonWay software, which is in widespread use by global construction companies, utilities, and government agencies.

Its an exciting time to be a part of biotech, said DevonWay CEO Chris Moustakas, and were thrilled to serve an industry that has such a huge impact on public health, disease prevention, and treatment. One of the challenges facing biotech today is maintaining a culture of innovation, which feeds the industrys rapid growth, while never sacrificing quality or safety. Were grateful for the opportunity to help the industry meet this challenge head-on.

Although many biotechnology companies use Quality Management Systems to help ensure quality and regulatory compliance, those systems often lack the flexibility needed to handle specific operational requirements. Continuous improvement software, such as that provided by DevonWay, is purpose-built to bridge the gap between operations and quality, and can serve the needs of both in a single closed-loop, FDA 21CFR11-compliant system.

Whether were brought on board to complement an existing QMS or outright replace it, our first and foremost priority is to serve the needs of our customers, says Matt Sacks, DevonWays Vice President of Sales. Unlike most systems currently servicing life sciences, our products can evolve without having to modify code. In an industry in which change is constant, this ability to facilitate change quickly and cost effectively provides a crucial advantage to our customers.

About DevonWay

Founded in San Francisco in 2005, DevonWay is a leading provider of continuous improvement and digital operations applications to customers across industries as diverse as energy generation, transmission and distribution, government, life sciences, and construction. By combining flexibility with ease of use, DevonWay helps high-reliability organizations transform, digitize, and continuously improve their operations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170404006173/en/

Originally posted here:
DevonWay Inc. Expands into Biotechnology Industry - Yahoo Finance

May 01, 2017 07:30 ET | Source: Research and Markets

Dublin, May 01, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/6hlgn5/animal

Source: Jain PharmaBiotech

About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

See the rest here:
Animal Biotechnology Technologies, Markets and Companies 2016-2026 - GlobeNewswire (press release)

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that interim results from a Phase II clinical trial of Pumas investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation, entitled Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2-positive early stage breast cancer: the CONTROL trial, was presented as a poster presentation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170404005596/en/

The main adverse event that has been seen to date in clinical trials of neratinib is diarrhea and more specifically grade 3 diarrhea. In the Phase III ExteNET trial of neratinib as extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with adjuvant Herceptin, 95.4% of the patients experienced all grade diarrhea and 39.8% of the patients experienced grade 3 or higher diarrhea (there was one event of grade 4 diarrhea). The CONTROL trial is an international, open-label, Phase II study investigating the use of loperamide prophylaxis with or without other agents in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 diarrhea.

In the CONTROL trial, patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy received neratinib daily for a period of one year. High dose loperamide prophylaxis was given for the first 2 cycles (56 days) of treatment. Initially, the loperamide dosing used was 16 mg on day 1, then 12 mg on days 2 and 3 and then 6-8 mg on days 4-56 (original dosing). The protocol was later amended to simplify the regimen such that patients took 12 mg on days 1-14 and 8 mg on days 15-56 (modified dosing). The CONTROL trial was also expanded to include two additional cohorts. One cohort received the combination of loperamide and budesonide and the other cohort received the combination of loperamide plus colestipol. Budesonide is a locally acting corticosteroid that the Company believes targets the inflammation identified in a preclinical model of neratinib-induced diarrhea and colestipol is a bile acid sequestrant that the Company believes targets the bile acid malabsorption also seen in preclinical models of neratinib-induced diarrhea.

The interim analysis of the trial presented in the poster included a total of 137 patients who received neratinib plus loperamide prophylaxis (28 patients taking the original dosing and 109 patients taking the modified dosing), 64 patients who received neratinib plus loperamide prophylaxis for 2 cycles and budesonide for 1 cycle, and 26 patients who received neratinib plus loperamide prophylaxis for 1 cycle and colestipol for 1 cycle.

The results of the trial showed that the incidence of grade 3 diarrhea for the 137 patients who received the loperamide prophylaxis was 30.7%. For the 137 patients who received the loperamide prophylaxis, the median number of grade 3 diarrhea episodes per patient was 1 and the median cumulative duration of grade 3 diarrhea was 3 days. For the 137 patients who received loperamide prophylaxis, 20.4% discontinued neratinib due to diarrhea.

For the 64 patients who received the combination of loperamide plus budesonide, the results of the trial showed that the incidence of grade 3 diarrhea was 23.4%. The median number of grade 3 diarrhea episodes per patient was 1 and the median cumulative duration of grade 3 diarrhea was 2 days. For the 64 patients who received loperamide plus budesonide prophylaxis, 9.4% discontinued neratinib due to diarrhea.

For the 26 patients who received the combination of loperamide plus colestipol, the results of the trial showed that the incidence of grade 3 diarrhea was 11.5%. The median number of grade 3 diarrhea episodes per patient was 2 and the median cumulative duration of grade 3 diarrhea was 2 days. For the 26 patients who received loperamide plus colestipol prophylaxis, no patient (0%) discontinued neratinib due to diarrhea. Further information is provided in Table 1 below:

Table 1: Characteristics of Treatment-Emergent Diarrhea

Loperamide

(original +

modified)

loperamide

loperamide

Loperamide

prn

a

In the ExteNET trial, higher grade (grade 2 and grade 3) diarrhea occurred early and persisted throughout the duration of the 12-month treatment period. In the CONTROL trial, in the loperamide prophylaxis, loperamide plus budesonide prophylaxis and loperamide plus colestipol prophylaxis arms, the results showed that higher grade diarrhea (grades 2 and 3) occurred early but did not typically recur. This is shown in more detail in Figure 1: Treatment Emergent Diarrhea, which is attached to this news release. In addition, a full copy of the poster that was presented at AACR is available on the Puma Biotechnology website.

During the course of the CONTROL trial there has been an increase in the proportion of patients previously treated with pertuzumab (mainly in the neoadjuvant setting). For the 55 patients in the loperamide prophylaxis cohort who received prior pertuzumab, the grade 3 diarrhea rate was 38.2% (Table 2). For the 82 patients who did not receive prior pertuzumab, the grade 3 diarrhea rate was 25.6%. For the 39 patients in the budesonide cohort who received prior pertuzumab, the grade 3 diarrhea rate was 10.3%. For the 25 patients in the budesonide cohort who did not receive prior pertuzumab, the grade 3 diarrhea rate was 36.0%. This analysis suggests that prior pertuzumab exposure may have led to a higher rate of grade 3 diarrhea in the CONTROL trial that was not effectively managed by loperamide prophylaxis alone but was more effectively managed by loperamide plus budesonide.

Table 2: Incidence of Grade 3 Diarrhea in CONTROL by Prior Pertuzumab Treatment

Loperamide Cohort

Budesonide Cohort

(n = 55)

(n = 82)

(n = 39)

(n = 25)

Dr. Carlos H. Barcenas, Assistant Professor, Department of Breast Medical Oncology and Associate Medical Director, Breast Cancer Survivorship Clinic for the University of Texas MD Anderson Cancer Center, said, We are pleased to see the reduction in incidence, severity and duration of neratinib-associated diarrhea when using the three antidiarrheal prophylaxis regimens tested so far in this study. When using either the loperamide prophylaxis, the loperamide plus budesonide prophylaxis or the loperamide plus colestipol prophylaxis, there appears to be a reduction in the incidence and severity of grade 3 diarrhea with neratinib. Importantly, the severe grade 2 and grade 3 diarrhea, when using the prophylaxis, appears to be acute, self-limiting and manageable. Although the study is still ongoing, we are encouraged that the addition of budesonide or colestipol appears to greatly improve the tolerability of neratinib as well. We look forward to completing the loperamide plus colestipol cohort.

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, We are pleased to see the reductions in the incidence of severe neratinib-related diarrhea in the CONTROL trial when using the loperamide, loperamide plus budesonide or loperamide plus colestipol regimens. The severe diarrhea appears to become more acute, whereby it does not typically recur after the first month. We are also very encouraged by the improvements in tolerability that have been seen to date in the budesonide and the colestipol cohorts. This is a marked improvement in tolerability over what was seen in the ExteNET trial and we look forward to continuing to monitor this in the loperamide plus colestipol cohort.

Read more here:
Puma Biotechnology (PBYI) Highlights Interim Results of Phase II CONTROL Trial of PB272 at AACR Meetings - StreetInsider.com

by Zacks Equity Research Published on April 04, 2017

ANTH APOP

Cellect Biotechnology Ltd. (APOP - Free Report) was a big mover last session, as the company saw its shares rise over 10% on the day. The move came after the company announced that it has received a formal notice of Intention to Grant for a patent covering a key method of treatment from the European Patent Office. This also led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.94 to $10.90 in the past one-month time frame.

None of the estimates for this stock were revised in the last 30 days and the Zacks Consensus Estimate also remained unchanged. Yesterdays price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Currently, Cellect Biotechnology carries a Zacks Rank #3 (Hold).

A better-ranked stock in the same industry is Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks #1 Rank stocks here.

Is APOP going up? Or down? Predict to see what others think: Up or Down

Zacks Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Here is the original post:
Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher - Zacks.com

New Jersey, United States:The new report has been added by Verified Market Research to provide a detailed overview of the Nanoparticles in Biotechnology and Pharmaceuticals Market. The study will help to better understand the Nanoparticles in Biotechnology and Pharmaceuticals industry competitors, the sales channel, Nanoparticles in Biotechnology and Pharmaceuticals growth potential, potentially disruptive trends, Nanoparticles in Biotechnology and Pharmaceuticals industry product innovations and the value / volume of size market (regional / national level, Nanoparticles in Biotechnology and Pharmaceuticals- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Nanoparticles in Biotechnology and Pharmaceuticals manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Nanoparticles in Biotechnology and Pharmaceuticals branch. Market participants can use the report to take a look at the future of the Nanoparticles in Biotechnology and Pharmaceuticals market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=CDN&utm_medium=003

The report examines the competitive environment scenario observed with key players in Nanoparticles in Biotechnology and Pharmaceuticals sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Nanoparticles in Biotechnology and Pharmaceuticals sales industry. According to studies, the Nanoparticles in Biotechnology and Pharmaceuticals sales market is very competitive and diverse due to global and local suppliers.

The Nanoparticles in Biotechnology and Pharmaceuticals Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Nanoparticles in Biotechnology and Pharmaceuticals market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Nanoparticles in Biotechnology and Pharmaceuticals market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Nanoparticles in Biotechnology and Pharmaceuticals for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=CDN&utm_medium=003

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology 3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=CDN&utm_medium=003

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

See the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size 2020 | Top Companies, Growth Overview, Technology, Latest Trends and Forecast 2026 -...

NEW YORK, April 3, 2017 /PRNewswire/ -- Use this report to: - Explore present and future strategies within the bioseparation systems market. - Learn about the upcoming developments, the holdups and the needs of the market. - Gain an insight into acquisition strategies and collaborations by companies.

Read the full report: http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html

- Receive an overview of the relevant patents related to the industry.

Highlights - The global market for bioseparation reached $18.4 billion in 2015. This market is expected to increase from $19.0 billion in 2016 to nearly $24.0 billion in 2021 at a compound annual growth rate (CAGR) of 4.7% for 2016-2021. - United States market for bioseparation is expected to grow from $7.0 billion in 2016 to nearly $9.3 billion at a CAGR of 5.9% from 2016 through 2021. - Emerging market for bioseparation is expected to grow from $7.0 billion in 2016 to $8.7 billion in 2021 at a CAGR of 4.4% from 2016 through 2021.

Introduction & Scope

Introduction

Study goals and objectives In recent years, the bioseparation systems (separation systems in biotechnology) segment has been one of growth in the biopharmaceuticals market. Primary use of these systems is for separation and purification of biological products. BCC Research's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for various bioseparation systems. This report explores present and future strategies within the bioseparation systems market. The market is categorized into liquid chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, labonachip, biochip, and magnetic separation. The upcoming developments of the market, the holdups and the needs of the market are discussed in this report. The classifications, comparisons and usage of these products are also portrayed in this report. A detailed analysis of the structure of the bioseparation systems industry has been conducted. The revenues have been broken down by region and sales figures are estimated for the fiveyear period from 2016 through 2021. The report also covers significant patents and their allotments in each category.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type in light of new technologies, growing competition, and changing customer needs.

Reasons for doing this study Bioseparation systems have a major place in the biopharmaceutical and biotechnology industry. Bioseparation is conducted on biological products like proteins, nucleic acids, and cell cultures, among others. The increasing demand for biopharmaceutical products is driving the global market for bioseparation systems. Increased research in life sciences, newer technological developments are taking bioseparation techniques to prodigious heights. Modern industries have now begun to explore the advantages of bioseparation systems in their production processes, which have led to a steady market. Research and development (R&D) spending, along with increasing competition and patent expiries are giving a new direction to the market. This study looks at almost all the systems affected by these factors.

Contributions of the study and for whom This study contributes to the areas of market growth for the manufacturers and users of bioseparation systems. Genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies will find this study to be of interest.

Scope of report The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a largescale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research. The scope of the study is global. BCC Research analyzes each market, new products and advancements, technologies involved, market projections and market shares. The geographical regions covered in the report are North America, Europe and emerging markets. The emerging market covers all countries like India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada, among others. The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, labonachip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., BioRad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Information sources Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of bioseparation systems. Data was gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

Methodology Read the full report: http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/separation-systems-for-commercial-biotechnology-300433779.html

Original post:
Separation Systems for Commercial Biotechnology - Yahoo Finance

AMSTERDAM, April 4, 2017 /PRNewswire/ --

Carl Zeiss Meditec AG has published and send a press release to the industry on March 27, 2017 mentioning that Carl Zeiss Meditec has won a patent infringement action before the District Court of Dsseldorf/Germany against VSY Biotechnology B.V. and its exclusive supplier Fritz Ruck Ophthalmologische Systeme GmbH based on European Patent 2 377 493 B1 of Carl Zeiss Meditec AG.

(Photo: http://mma.prnewswire.com/media/485639/VSY.jpg )

VSY Biotechnology considers it important to note that this is a ruling by the German Court of First Instance. VSY Biotechnology has the right to and will appeal this judgement with the Higher District Court and if necessary with the Federal Supreme Court in Germany. It is expected that a final ruling on the infringement may take several years and German Court's ruling is only effective in Germany but not in all over the world.

VSY Biotechnology B.V. reserves its right to seek material and moral indemnity for all direct and indirect damages of VSY Biotechnology on basis of unfair competition and defamation due to incomplete press release of Carl Zeiss dated March 27, 2017. Further VSY Biotechnology will ask for all damages they may suffer from the decision of the First German Court in case of District Court or Federal Court rule in favor of VSY Biotechnology.

Additionally, VSY Biotechnology applied for invalidation of Zeiss Patent EP 2 377 493 B1 before EPO with the claim of Zeiss Patent has lack of novelty, lack of inventive step, therefore unpatentable.

VSY filed opposition against Zeiss patent

VSY Biotechnology B. V. (VSY) has, amongst others, filed an opposition against Carl Zeiss Meditec A.G.'s (Zeiss) European patent EP 2 377 493 B1 "Method for manufacturing aphakic intraocular lens" (EP'493) with the European Patent Office (EPO) on May 6, 2016. Zeiss acquired EP'493 from the German IP advisers IP Strategists GmbH who acquired the patent from the Japanese company Menicon Co..VSY is of the opinion that EP'493 does not fulfil the requirements of patentability as it lacks novelty and inventive step, is insufficiently disclosed and includes extension of subject matter.

The patent regards Trifocal intraocular lenses. Trifocal lenses of Zeiss are AT LISA tri and the AT LISA tri toric.

The opposition is still pending.

All details of the opposition can be found on: https://register.epo.org/application?number=EP09837427&lng=de&tab=doclist

About VSY Biotechnology BV

VSY Biotechnology is one of the leading companies in Industry of ophthalmology focusing on cataract surgery, producing premium intra ocular lenses and viscoelastics. For more information, please visit company website. http://www.vsybiotechnology.com.

Read the original post:
Patent Case of Carl Zeiss Meditec AG and VSY Biotechnology B.V. - Yahoo Finance

Agricultural biotechnology marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 74.55 billion by 2027 growing at a CAGR of 9.94% in the above-mentioned forecast period. Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.

The Agricultural biotechnology market report keenly considers the market type, size of the organization, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa to analyse the data. Thus, this market research report encompasses various parameters of the market. The analysis and estimations carried out via this Agricultural biotechnology report helps to get the details about the product launches, future products, joint ventures, marketing strategy, developments, mergers and acquisitions and effect of the same on sales, marketing, promotions, revenue, import, export, and CAGR values.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

The major players covered in the agricultural biotechnology market report areKWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Major Topics Covered in this Report:

Chapter 1 Study Coverage

Chapter 2 Executive Summary

Chapter 3 Market Size by Manufacturers

Chapter 4 Production by Regions

Chapter 5 Consumption by Regions

Chapter 6 Market Size by Type

Chapter 7 Market Size by Application

Chapter 8 Manufacturers Profiles

Chapter 9 Production Forecasts

Chapter 10 Consumption Forecast

For More Insights Get Detailed TOChttps://www.databridgemarketresearch.com/toc/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines,geneticengineering, and others.On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.On the basis of organism type, theagricultural biotechnologymarket is divided into plants, animals, microbes, and others.On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.

Inquiry For Customize Report With Discount Athttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Original post:
Global Agricultural Biotechnology Market 2027:Rising Demand And Forecast Analysis By Major Players Like Evogene Ltd., Canonic ltd., Bayer AG, Valent...

Vir Biotechnology (NYSE:VIR) shares reached a new 52-week high on Thursday . The stock traded as high as $16.60 and last traded at $16.52, with a volume of 2924 shares changing hands. The stock had previously closed at $15.26.

A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Vir Biotechnology from a hold rating to a sell rating in a research report on Saturday, January 11th. Goldman Sachs Group began coverage on shares of Vir Biotechnology in a research report on Tuesday, November 5th. They issued a buy rating and a $37.00 target price for the company. Robert W. Baird began coverage on shares of Vir Biotechnology in a research note on Wednesday, November 13th. They set a neutral rating for the company. Cowen began coverage on Vir Biotechnology in a report on Tuesday, November 19th. They set a buy rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an overweight rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has a consensus rating of Buy and an average target price of $29.00.

The stock has a 50-day moving average price of $12.86.

Vir Biotechnology (NYSE:VIR) last released its quarterly earnings results on Tuesday, November 19th. The company reported ($4.60) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($3.71) by ($0.89). The firm had revenue of $1.40 million for the quarter.

About Vir Biotechnology (NYSE:VIR)

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Read More: What is a Call Option?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:
Vir Biotechnology (NYSE:VIR) Reaches New 52-Week High at $16.60 - Riverton Roll

Biotechnology is a technological application that uses living organisms, biological systems or derivatives to produce or modify products or processes for specific use. Biotechnology encompasses a wide range of procedures required for modifying living organisms to fulfill various demands for domestic as well as industrial applications. Thus, biotechnology is a general term that is used for a wide range of techniques that are involved in the production, transformation or degradation of the desired product. Biotechnology based chemicals are the products that are manufactured by applying various techniques such as fermentation. Biotechnology based chemicals comprises polyhydroxyalkanoates, lactic acid, lysine, citric acid, glutamic acid and threonine. The technology used in manufacturing biotechnology based chemicals are simple however, the entire production process should be carried out under the supervision of trained personnel. Glutamic acid is the most widely used amino acid manufactured as well as consumed in the world. Biotechnology based chemicals find application in pharmaceuticals, food industry, animal feed and consumer goods manufacturing industries among others.

Pharmaceutical industry is the largest consumer of biotechnology based chemicals. The growing demand for natural medicines than that compared to synthetic chemicals is expected to augment the overall demand for biotechnology based chemicals. In addition, growing awareness of the several side effects associated with the chemical drugs is expected to boost the overall biotechnology based chemicals market. The animal feed industry is also one of the major consumers of biotechnology based chemicals market. The growing demand for lysine in animal feed is expected to boost the overall demand for biotechnology chemicals market. Lactic acid finds applications in a wide range of industries. The growing demand for manufacturing polylactic acid (PLA) plastics boost the demand for lactic acid which in turn is expected to augment the overall biotechnology based chemicals market. However, high cost associated with the manufacturing of biotechnology based chemicals is expected to restrain the overall growth of the market.

The growing demand for pharmaceutical products has expected to augment the overall demand for biotechnology based chemicals in China. China is the largest consumer of biotechnology based chemicals market. The growing demand for citric acid especially from the food and beverage industry in China is expected to augment the overall demand for biotechnology based chemicals market. North America is expected to be the next largest consumer of biotechnology based chemicals owing to the growing consumer preference for natural products. The demand for biotechnology based chemicals is expected to grow rapidly owing to the presence of dominant animal feed and other end use industries in Europe. Lysine is a crucial ingredient used in the animal feed for swine and poultry feeds. Thus, the growing demand for animal feed is expected to boost the overall demand for biotechnology based chemicals market. Rest of Asia Pacific is expected to experience rapid growth in the demand for biotechnology based chemicals owing to the growing pharmaceutical industry in the region. However, Rest of the World is expected to exhibit sluggish growth in the demand for biotechnology based chemicals in the next few years.

To Get Glimpse of what our report offers,Ask for a Report Brochurehere

Kemin, BioAmber Inc. and Stora Enso are some of the major participants in the biotechnology based chemicals market. The companys present in the focus mainly towards research as they intend to introduce innovative products in the market.

This post was originally published on Market Research Sheets

More:
Biotechnology Based Chemicals Market Scope, Summary, Overview, Research Methodology and Forecast to 2020 - Market Research Sheets

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. For example, we sympathize with anyone who was caught holding Avecho Biotechnology Limited (ASX:AVE) during the five years that saw its share price drop a whopping 94%. On top of that, the share price has dropped a further 33% in a month.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

See our latest analysis for Avecho Biotechnology

We don't think that Avecho Biotechnology's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. It would be hard to believe in a more profitable future without growing revenues.

Over five years, Avecho Biotechnology grew its revenue at 6.2% per year. That's a fairly respectable growth rate. So the stock price fall of 44% per year seems pretty steep. The truth is that the growth might be below expectations, and investors are probably worried about the continual losses.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

ASX:AVE Income Statement, November 12th 2019

Take a more thorough look at Avecho Biotechnology's financial health with this free report on its balance sheet.

We're pleased to report that Avecho Biotechnology shareholders have received a total shareholder return of 33% over one year. That certainly beats the loss of about 43% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Here is the original post:
If You Had Bought Avecho Biotechnology (ASX:AVE) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today - Yahoo Finance

Morning Times

Puma Biotechnology Inc (PBYI) Shares Bought by BB Biotech AG The Cerbat Gem Puma Biotechnology logo BB Biotech AG boosted its position in shares of Puma Biotechnology Inc (NYSE:PBYI) by 1.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 245,616 shares of the biopharmaceutical ... Puma Biotechnology, Inc. (NasdaqGS:PBYI) Company Valuation & Investor ReviewUnion Trade Journal Puma Biotechnology (PBYI) Research Analysts' Weekly Ratings UpdatesBNB Daily (blog) Puma Biotechnology Inc (PBYI) Earns Buy Rating from Stifel NicolausStock Observer BBNS -Chaffey Breeze -Sports Perspectives -SEC.gov all 22 news articles »

Originally posted here:
Puma Biotechnology Inc (PBYI) Shares Bought by BB Biotech AG - The Cerbat Gem

Editor-in-Chief

Volume Editors

Section Editors

General Preface

Nomenclature Guidelines

Permission Acknowledgments

1.01. Introduction

1.02. Amino Acid Metabolism

Glossary

1.02.1. Introduction

1.02.2. General Properties, Classification, and Structure of Amino Acids

1.02.3. Biosynthesis of Amino Acids

1.02.4. Catabolism of Amino Acids

1.02.5. Important Biomolecules Synthesized from Amino Acids

1.03. Enzyme Biocatalysis

Glossary

1.03.1. Introduction to Enzymes

1.03.2. Enzyme Kinetics

1.03.3. Enzyme Engineering

1.03.4. Enzyme Production

1.03.5. Immobilized Enzymes

1.03.6. Enzyme Applications

1.03.7. Conclusions

1.04. Immobilized Biocatalysts

1.04.1. Introduction: Definitions and Scope

1.04.2. Applications of Immobilized Enzymes

1.04.3. Methods of Enzyme Immobilization

1.04.4. Properties of Immobilized Enzymes

1.04.5. Evaluation of Enzyme Immobilization

1.04.6. Heterogeneous Biocatalysis

1.04.7. Future Prospects for Immobilized Biocatalysts

1.05. Lipids, Fatty Acids

Glossary

1.05.1. Introduction

1.05.2. Structure of Fatty Acids

1.05.3. Nomenclature

1.05.4. Form in the Cell

1.05.5. What Do Lipids Do?

1.05.6. Biosynthesis of Fatty Acids and Lipids

1.05.7. Biochemistry of Lipid Accumulation

1.06. DNA Cloning in Plasmid Vectors

Glossary

1.06.1. Introduction

1.06.2. Cloning Vectors: Replication Origins and Partition Regions

1.06.3. Cloning Vectors: Selection Markers

1.06.4. Preparing DNA Fragments for Ligation

1.06.5. Ligation Systems

1.06.6. Methods of Bacterial and Yeast Transformation

1.06.7. Exploitation of Bacteriophage Packaging for DNA Cloning in Plasmid Vectors

1.06.8. Screening of Plasmid Clones in Bacteria for the Desired Recombinant Plasmids

1.06.9. Vector-Implemented Systems for the Direct Selection of Recombinant Plasmids

1.06.10. Direct Selection of Recombinant Plasmids Involving Restriction Enzyme Digestion of the Ligation Mixture

1.06.11. Particular Features of Oligonucleotides Cloning

1.06.12. Particular Features of Cloning of PCR Amplicons

1.06.13. Introduction of Deletions into Plasmids

1.06.14. Instability of Recombinant Plasmids

1.06.15. DNA Cloning Using Site-Specific Recombination

1.06.16. DNA Cloning Using Homologous (General) Recombination

1.06.17. Employment of Transposons for In Vivo Cloning and Manipulation of Large Plasmids

1.06.18. Conclusion

1.07. Structure and Biosynthesis of Glycoprotein Carbohydrates

Glossary

Acknowledgments

1.07.1. Introduction

1.07.2. Monosaccharide Structure

1.07.3. Oligosaccharide Structure

1.07.4. Biosynthesis of Glycoproteins

1.07.5. Glycosylation of Therapeutic Glycoproteins

1.08. Nucleotide Metabolism

Glossary

1.08.1. Introduction

1.08.2. Synthesis of Phosphoribosyl Diphosphate (PRPP)

1.08.3. Purine Biosynthesis

1.08.4. Pyrimidine Biosynthesis

1.08.5. Nucleoside Triphosphate Formation

1.08.6. Deoxyribonucleotide Biosynthesis

1.08.7. Nucleotide Salvage

1.08.8. Purine and Pyrimidine Catabolism

1.08.9. Regulation of Gene Expression in Bacterial Nucleotide Synthesis

1.08.10. Exploitation of the Knowledge of Nucleotide Metabolism in Biotechnology

1.09. Organic Acids

Glossary

1.09.1. Introduction

1.09.2. Citric Acid

1.09.3. Gluconic Acid

1.09.4. Lactic Acid

1.09.5. Itaconic Acid

1.09.6. Other Acids

1.10. Peptides and Glycopeptides

Glossary

1.10.1. Introduction

1.10.2. Peptide Hormones

1.10.3. Neuropeptides

1.10.4. Antibacterial Peptides

1.10.5. Glycosylation Is a Common and Important Post-Translational Modification of Peptides

1.10.6. Common Glycosidic Linkages

1.10.7. Peptide Synthesis

1.10.8. Glycopeptide Synthesis

1.10.9. Peptides and Glycopeptides as Models of Proteins and Glycoproteins

1.10.10. Application of Synthetic Peptides and Glycopeptides for the Treatment of Disease

More here:
Comprehensive Biotechnology - 2nd Edition